Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

Core Insights - Rege Nephro Co., Ltd. has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, enhancing its operational capabilities for clinical trials in the United States [1][3] - Tamibarotene (RN-014) is currently in a Phase 2 clinical trial in Japan for autosomal dominant polycystic kidney disease (ADPKD), with plans to initiate trials in the U.S. following efficacy and safety confirmation [2][5] - The acquisition includes critical data and contracts that will streamline Rege Nephro's clinical trial operations [3] Company Overview - Rege Nephro, founded in 2019, is a clinical-stage biotech company focused on developing therapeutics and cell therapies for kidney, liver, and pancreas-related diseases [4] - The company leverages technology based on research from Prof. Kenji Osafune at Kyoto University [4] Product Information - RN-014 is a retinoic acid receptor (RAR) agonist aimed at suppressing cyst formation and improving renal function in ADPKD patients [5] - The Phase 2 clinical trial for RN-014 began in December 2023, with the second stage enrollment completed and no significant safety concerns reported [5]